Clinical Trials Directory

Trials / Conditions / Recurrent Ovarian Endometrioid Adenocarcinoma

Recurrent Ovarian Endometrioid Adenocarcinoma

10 registered clinical trials studyying Recurrent Ovarian Endometrioid Adenocarcinoma — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingPembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patien
NCT05231122
Roswell Park Cancer InstitutePhase 2
RecruitingTesting Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovaria
NCT05950464
National Cancer Institute (NCI)Phase 1
RecruitingVaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity
NCT05920798
Mayo ClinicPhase 1 / Phase 2
WithdrawnComparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent
NCT05295589
National Cancer Institute (NCI)Phase 2
Active Not RecruitingComparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800
National Cancer Institute (NCI)Phase 2
Active Not RecruitingA Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With
NCT04092270
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTesting the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurr
NCT04034927
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631
National Cancer Institute (NCI)Phase 2
Active Not RecruitingPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R
NCT02839707
National Cancer Institute (NCI)Phase 2 / Phase 3
Active Not RecruitingTesting the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared
NCT02446600
National Cancer Institute (NCI)Phase 3